Similar articles

• A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

  Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 study group. Thal LJ, et al. Neuropsychopharmacology. 2005 Jun;30(6):1204-15. doi: 10.1038/sj.npp.1300690. Neuropsychopharmacology. 2005. PMID: 15742005 Clinical Trial.
• [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].

  Jacus JP, Dupont MP, Herades Y, Pelix C, Large H, Baud M. Jacus JP, et al. Encephale. 2014 Apr;40(2):180-7. doi: 10.1016/j.encep.2013.10.003. Epub 2014 Mar 11. Encephale. 2014. PMID: 24630532 Review. French.
• Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

  Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC; AIBL Research Group. Lim YY, et al. Brain. 2014 Jan;137(Pt 1):221-31. doi: 10.1093/brain/awt286. Epub 2013 Oct 30. Brain. 2014. PMID: 24176981
• Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.

  Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H. Okamura N, et al. Am J Psychiatry. 2002 Mar;159(3):474-6. doi: 10.1176/appi.ajp.159.3.474. Am J Psychiatry. 2002. PMID: 11870015
• Mild cognitive impairment in older people.

  Burns A, Zaudig M. Burns A, et al. Lancet. 2002 Dec 14;360(9349):1963-5. doi: 10.1016/S0140-6736(02)11920-9. Lancet. 2002. PMID: 12493278 Review.